利拉鲁肽、胰岛素强化、二甲双胍联合治疗肥胖型2型糖尿病的疗效分析  

Efficacy analysis of liraglutide,insulin enhancement and metformin combined treatment of obese type 2 diabetes mellitus

作　　者：陈曦 代瑞环 李金学[2] 漆波 CHEN Xi;DAI Rui-huan;LI Jin-xue;QI Bo(Department of Endocrinology,Jiangyou 903 Hospital,Jiangyou 621700,China)

机构地区：[1]江油市九〇三医院内分泌科,四川江油621700 [2]绵阳市中心医院心胸外科,四川绵阳621000 [3]江油市九〇三医院重症医学科,四川江油621700

出　　处：《武警后勤学院学报（医学版）》2021年第9期65-66,69,共3页Journal of Logistics University of PAP（Medical Sciences）

摘　　要：【目的】探讨利拉鲁肽、胰岛素强化、二甲双胍联合治疗肥胖型2型糖尿病(T2DM)的疗效。【方法】选取我院80例肥胖型T2DM患者,根据简单随机分类法分为对照组和观察组,各40例。对照组采取二甲双胍联合胰岛素强化治疗,观察组加用利拉鲁肽治疗。对比两组临床疗效,治疗前后体质指数(BMI)、血糖、血脂水平、胰岛功能和不良反应。【结果】观察组治疗总有效率高于对照组(P<0.05);观察组BMI、血糖及血脂水平均低于对照组(均P<0.05);观察组胰岛功能改善情况优于对照组(P<0.05);两组不良反应总发生率差异不显著(P>0.05)。【结论】利拉鲁肽、胰岛素强化、二甲双胍联合治疗肥胖型T2DM疗效显著,可改善患者临床症状,降低患者体质指数,降低血糖水平,不增加低血糖风险。【Objective】To investigate the efficacy of liraglutide,insulin enhancement and metformin in the treatment of obese type 2 diabetes mellitus(T2DM).【Methods】A total of 80 obese T2DM patients in our hospital were selected and divided into control group and observation group according to simple random classification,with 40 cases in each group.The control group was treated with metformin combined with insulin,and the observation group was treated with liraglutide.Clinical efficacy,body mass index(BMI),blood glucose and lipid levels,islet function and adverse reactions before and after treatment were compared between the two groups.【Results】The total effective rate of observation group was higher than that of control group(P<0.05).BMI,blood glucose and lipid levels in observation group were lower than those in control group(P<0.05).The improvement of islet function in observation group was better than that in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P>0.05).【Conclusion】Liraglutide,insulin enhancement and metformin combined treatment of obese T2DM has significant efficacy,which can improve clinical symptoms,reduce BMI and blood glucose level without increasing the risk of hypoglycemia.

关 键 词：利拉鲁肽 胰岛素强化 二甲双胍 肥胖型2型糖尿病 血糖 

分 类 号：R587.1[医药卫生—内分泌]